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Abstract  Different  phenotype-based  techniques  and  molecular  tools  were  used  to  describe
the distribution  of  different  Achromobacter  species  in  patients  with  cystic  fibrosis  (CF)  in
Argentina, and  to  evaluate  their  antibiotic  resistance  profile.  Phenotypic  identification  was
performed  by  conventional  biochemical  tests,  commercial  galleries  and  MALDI-TOF  MS.  Genetic
approaches  included  the  detection  of  A.  xylosoxidans  specific  marker  blaoxa-114,  the  amplifi-
cation and  sequencing  of  the  16S  rRNA  gene,  nrdA  and  blaOXA complete  sequence,  and  MLST
analysis. Phenotypic  approaches,  even  MALDI-TOF,  rendered  inconclusive  or  misleading  results.
On the  contrary,  concordant  results  were  achieved  with  the  nrdA  sequencing  or  sequence  type
(ST) analysis,  and  the  complete  blaOXA sequencing,  allowing  a  reliable  discrimination  of  differ-
ent Achromobacter  species.  A.  xylosoxidans  accounted  for  63%  of  Achromobacter  infections  and
A. ruhlandii  accounted  for  17%.  The  remaining  species  corresponded  to  A.  insuavis, A.  dolens,
A. marplatensis  and  A.  pulmonis.  Antimicrobial  susceptibilities  were  determined  by  the  agar
 to  CLSI  guidelines.  Piperacillin,  piperacillin/tazobactam  and  car-
ctive  antibiotics.  However,  the  emergence  of  carbapenem-resistant
nclusion,  prompt  and  accurate  identification  tools  were  necessary  todilution method  according
bapenems  were  the  most  a
isolates  was  detected.  In  co∗ Corresponding author.
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determine  that  different  Achromobacter  species  may  colonize/infect  the  airways  of  patients
with CF.  Moreover,  antimicrobial  therapy  should  be  administered  based  on  the  susceptibility
profile of  individual  Achromobacter  sp.  isolates.
© 2019  Asociación  Argentina  de  Microbioloǵıa.  Published  by  Elsevier  España,  S.L.U.  This  is  an









Diversidad  de  las  especies  de  Achromobacter  recuperadas  de  pacientes  con  fibrosis
quística  en  Argentina
Resumen  Se  emplearon  diversas  técnicas  fenotípicas  y  moleculares  para  describir  la  distribu-
ción de  diferentes  especies  del  género  Achromobacter  en  pacientes  con  fibrosis  quística  (FQ)
en Argentina,  y  se  evaluó  el  perfil  de  resistencia  a  los  antibióticos.  Se  realizó  la  identificación
fenotípica  por  pruebas  bioquímicas  convencionales,  galerías  comerciales  y  MALDI-TOF  MS.  El
enfoque genético  incluyó  la  detección  del  marcador  especie-específico  de  A.  xylosoxidans
blaoxa-114,  la  amplificación  y  la  secuenciación  de  los  genes  ARNr  16S,  nrdA  y  secuencia  completa
de blaOXA,  y  el  análisis  por  MLST.  Los  enfoques  fenotípicos,  incluso  la  técnica  de  MALDI-TOF,
proporcionaron  resultados  no  concluyentes  o  erróneos.  Por  el  contrario,  se  obtuvieron  resulta-
dos concordantes  entre  la  secuenciación  del  gen  nrdA  o  el  análisis  de  secuenciotipos  (ST)  y  la
secuenciación  completa  de  blaOXA,  lo  que  permitió  una  discriminación  confiable  de  las  difer-
entes especies  de  Achromobacter.  A.  xylosoxidans  representó  el  63%  de  las  infecciones  por
Achromobacter  y  A.  ruhlandii  representó  el  17%.  Las  especies  restantes  correspondieron  a  A.
insuavis, A.  dolens,  A.  marplatensis  y  A.  pulmonis.  Se  determinó  la  sensibilidad  a  antimicro-
bianos por  el  método  de  dilución  en  agar  de  acuerdo  al  CLSI.  Los  antibióticos  más  activos  fueron
piperacilina,  piperacilina/tazobactam  y  carbapenemes.  Sin  embargo,  se  detectó  la  emergencia
de aislamientos  resistentes  a  carbapenemes.  En  conclusión,  resultaron  necesarias  herramientas
de identificación  rápida  y  precisas  para  determinar  las  diferentes  especies  del  género  Achro-
mobacter  capaces  de  colonizar/infectar  las  vías  respiratorias  de  los  pacientes  con  FQ.  Asimismo,
la terapia  antimicrobiana  debería  llevarse  a  cabo  en  función  del  perfil  de  sensibilidad  de  los
aislamientos  individuales  de  Achromobacter  spp.
© 2019  Asociación  Argentina  de  Microbioloǵıa.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un







































chromobacter  spp.  are  increasingly  recognized  as  emerging
athogens  in  patients  with  cystic  fibrosis  (CF)20.  Reported
ates  of  Achromobacter  colonization/infection  in  individ-
als  with  CF,  vary  between  2%  and  17.9%,  and  display
 rising  tendency  worldwide3,10.  Achromobacter  xylosoxi-
ans  is  the  most  frequent  species  recovered  within  this
enus,  however  other  species  have  been  associated  with
uman  infections15,17.  Moreover,  clinical  isolates  are  mostly
eferred  as  A.  xylosoxidans  given  that  the  accurate  species
dentification  of  Achromobacter  isolates  is  difficult.
Conventional  phenotypic  methods  have  been  commonly
sed  for  bacterial  identification  of  Achromobacter  spp.  in
any  clinical  laboratories,  as  their  implementation  and  cost
ake  them  more  affordable.  Since  these  classical  meth-
ds  yield  unclear  results,  and  generally  fail  to  differentiate
etween  species  of  the  genus,  molecular  methods  have  been
roposed  as  complementary  or  alternative  procedures.
Amplification  and  sequencing  of  the  16S  rRNA  coding
ene,  which  constitutes  a  useful  method  in  the  iden-




iscriminate  between  species  of  Achromobacter5,12.  In
011,  Turton  et  al.  proposed  the  amplification  of  the
laOXA-114 gene  for  rapid  and  accurate  A.  xylosoxidans
dentification9,21. Moreover,  in  2013  we  described  the  pres-
nce  of  blaOXA-258,  blaOXA-364, and  blaOXA-243 in  Achromobacter
uhlandii,  Achromobacter  dolens, and  Achromobacter
nsuavis,  respectively,  as  species-specific  markers  useful  for
acterial  identification14,19.  Simultaneously,  Spilker  et  al.
roposed  the  amplification  and  sequencing  of  an  inner
ragment  of  the  nrdA  gene,  one  of  those  included  in
he  multilocus  sequence  typing  (MLST)  scheme,  as  a  pre-
ise  method  for  the  identification  of  different  species  of
chromobacter17.
MALDI-TOF  MS  has  emerged  as  a  revolutionary  tech-
ique  for  rapid  bacterial  identification.  This  method  has
een  shown  to  be  more  rapid,  accurate  and  cost-efficient
han  conventional  phenotypic  techniques  or  genotypic
pproaches.  However,  its  performance  is  uncertain  in  infre-
uent  species.
In  this  study,  different  phenotype-based  techniques  and
olecular  tools  were  conducted  to  describe  the  distribu-
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Forty-one  non-related  Achromobacter  spp.  clinical  isolates,
recovered  from  patients  with  CF  at  6  healthcare  centers  in
Argentina  during  1996--2013  were  included.  Isolates  were
mainly  obtained  from  respiratory  secretions  (Table  S1,  sup-
plementary  material).
Phenotypic  identification
Phenotypic  identification  was  performed  by  biochemical
tests  according  to  Yabuuchi  et  al.23 and  Vandamme  et  al.22
The  biochemically-based  commercial  system,  API  20NE
(bioMèrieux)  was  also  conducted.
MALDI-TOF  MS  identification  was  performed  using  a
Microflex  MALDI-OF  MS  instrument  (Bruker  Daltonics,  GmbH,
Germany)  and  FlexControl  3.0  software  (Bruker  Daltonics).
Identification  scores  ≥2.0  were  accepted  for  a  reliable  iden-
tification  at  species  level  and  scores  between  ≥1.7  and  ≤2.0
were  accepted  for  identification  at  genus  level.  Scores  <1.7
indicated  no  reliable  identification8.
Genotypic  identification
The  16S  rRNA  gene  was  amplified  by  PCR  as  previously
described13.  Purified  amplicons  were  sequenced  in  both
strands  using  an  ABI  Prism  DNA  3700  sequencer  and  com-
pared  with  databases  using  the  NCBI’s  BLAST  tool.
The  nrdA  sequence  was  achieved  according
to  Spilker  et  al.  and  compared  with  databases
(https://pubmlst.org/achromobacter/)17.
The  presence  of  A.  xylosoxidans  species-specific  marker,
blaOXA-114,  was  investigated  by  PCR  amplification  as  previ-
ously  described  by  Turton  et  al.21 The  complete  blaOXA-114,
blaOXA-258,  blaOXA-364 and  blaOXA-243 sequences  intrinsic  for
A.  xylosoxidans, A.  ruhlandii,  A.  dolens,  and  A.  insuavis,
respectively,  were  amplified  according  to  Traglia  et  al.19
Amplicon  sequences  were  compared  with  those  of  all  the
different  blaOXA variants  deposited  in  GenBank.
Multilocus  sequence  typing  analysis
A  multilocus  sequence  typing  (MLST)  scheme  was  con-
ducted  to  identify  those  isolates  which  could  not  be
unambiguously  identified  by  nrdA  sequencing.  For  this  pur-
pose,  amplification  and  sequencing  of  inner  fragments  of
seven  housekeeping  genes  were  performed  and  the  cor-
responding  allele  profiles  and  sequence  types  (ST)  were
assigned  according  to  the  Achromobacter  MLST  website
(http://pubmlst.org/achromobacter/)18.Antimicrobial  susceptibility  testing
Minimal  inhibitory  concentrations  (MIC)  were  determined  for






efoxitin,  ceftazidime,  cefepime,  piperacillin/tazobactam,
mipenem,  meropenem,  ciprofloxacin,  levofloxacin,
mikacin,  kanamycin,  gentamicin,  trimethoprim-
ulfamethoxazole,  tetracycline  and  colistin.  Antimicrobial
usceptibilities  were  determined  by  the  agar  dilution
ethod  according  to  Clinical  and  Laboratory  Standards
nstitute  (CLSI)  recommendations.  The  susceptibility  break-
oints  used  in  this  study  were  those  established  for  other
on-Enterobacteriaceae6.
esults
henotypic  identification  results  are  shown  in  Table  S1.
ccording  to  classical  biochemical  methods,  27/41  isolates
ere  identified  as  A.  xylosoxidans,  the  remaining  ones
eing  identified  as  Achromobacter  spp.  Using  the  API  20NE
ommercial  gallery,  39/41  corresponded  to  A.  xylosoxidans.
ased  on  MALDI-TOF  MS  data,  all  isolates  except  one  were
onsistent  with  A.  xylosoxidans. Species  identification  was
chieved  in  25/40  isolates  with  score  ≥2,  while  15/40  dis-
layed  scores  from  1.7  to  1.9.  None  of  the  samples  presented
core  <1.7.
The  16S  rRNA  sequences  obtained  for  the  isolates
ncluded  in  this  study  displayed  about  99%  identity  with
hose  deposited  for  different  species  of  Achromobacter,
eing  unable  to  discriminate  among  them.
The  results  of  the  other  genetic  approaches  performed
n  this  study  are  shown  in  Table  1.  The  amplification  of
laOXA-114 proposed  by  Turton  et  al.21 yielded  positive  results
n  39/41  isolates,  indicating  that  they  corresponded  to
 xylosoxidans. However  discrepancies  were  observed  in
3/39  isolates  when  comparing  these  results  with  those
btained  using  other  molecular  methods.  Based  on  these
ethods,  the  13  isolates  were  finally  identified  as  Achro-
obacter  species  other  than  A.  xylosoxidans  (Table  1).
nrdA  gene  sequencing17 allowed  to  identify  33/41
solates.  In  the  remaining  isolates,  nrdA  sequences
orresponded  to  alleles  that  were  not  deposited  in
ubmlst.org/achromobacter.  For  these  isolates,  identifica-
ion  was  performed  based  on  the  complete  MLST  Scheme18.
ifferent  alleles  of  blaOXA-114 were  observed  in  the  26  isolates
dentified  as  A.  xylosoxidans  by  nrdA  gene  sequencing17;
ven,  3  new  blaOXA-114 variants  were  identified  in  this
tudy  (accession  numbers:  MK388911,  MK388912,  MK388913)
Table  1).  These  new  blaOXA-114 variants  were  designated
s  OXA-114i,  OXA-790  and  OXA-791  by  NCBI.  Then  again,
n  those  isolates  identified  as  A.  insuavis,  A.  dolens  and
.  ruhlandii  by  nrdA  gene  sequencing  or  ST  analysis,  the
laOXA sequences  displayed  99--100%  identity  to  blaOXA-243,
laOXA-364 and  blaOXA-258, respectively.  Two  new  blaOXA-364 vari-
nts  were  identified  (MK388909,  MK388910)  (Table  1).  These
laOXA-364 variants  were  designated  as  OXA-787  and  OXA-789
y  NCBI.  No  blaOXA amplicons  could  be  obtained  in  any  of  the
solates  identified  by  nrdA  sequencing17 as  Achromobacter
arplatensis  and  Achromobacter  pulmonis  (Table  1).
A.  xylosoxidans  accounted  for  63.4%  of  Achromobac-
er  colonization/infections  in  this  study,  while  A.  ruhlandii
ccounted  for  17.1%.  The  remaining  species  corresponded
o  A.  dolens  (9.8%),  A.  insuavis  (4.9%),  A.  marplatensis
2.4%)  and  A.  pulmonis  (2.4%).  According  to  previous  stud-
es  performed  in  the  UK7,  Spain4, France2,  USA17,  Brazil16
16  M.  Papalia  et  al.
Table  1  Comparison  of  different  genotypic  methods  for  the  identification  of  Achromobacter  spp.  isolates
Isolate  Year  of  isolation  nrdA  analysis17 and  ST  PCR  blaOXA21 blaOXA19
A39  2008  A.  xylosoxidans +  blaOXA-114m
A43  2009  A.  dolens  +  blaOXA-787 (MK388909)
A45 2011  A.  pulmonis  −  --
A46 2011  A.  marplatensis  −  --
A49 2012  A.  xylosoxidans  +  blaOXA-790 (MK388911)
A50 2012  A.  dolens  +  blaOXA-789 (MK388910)
A51 2012  A.  xylosoxidans  +  blaOXA-114o
A52  2004  A.  xylosoxidans  +  blaOXA-791 (MK388912)
A53 2012  A.  dolens +  blaOXA-364a
A79  2012  A.  xylosoxidans +  blaOXA-114i (MK388913)
A113 2009  A.  xylosoxidans +  blaOXA-790 (MK388911)
A131 2012  A.  ruhlandii  +  blaOXA-258a
A134  2013  A.  ruhlandii  +  blaOXA-258a
38  2002  ST  148  (A.  ruhlandii)a +  blaOXA-258a
39  2002  ST  148  (A.  ruhlandii)a +  blaOXA-258a
67  2004  ST  148  (A.  ruhlandii)a +  blaOXA-258a
79  2004  ST  64  (A.  insuavis)a +  blaOXA-243a
80  2004  ST  14  (A.  ruhlandii)a +  blaOXA-258a
114  2002  ST  165  (A.  insuavis)a +  blaOXA-243e
319  1996  ST  43  (A.  ruhlandii)a +  blaOXA-258b
336  2010  ST  164  (A.  dolens)a +  blaOXA-364a
A1  2004  A.  xylosoxidans  +  blaOXA-114g
A2  1995  A.  xylosoxidans  +  blaOXA-114i
A3  2006  A.  xylosoxidans  +  blaOXA-114f
A4  2003  A.  xylosoxidans  +  blaOXA-114g
A5  2002  A.  xylosoxidans  +  blaOXA-114l
A6  2007  A.  xylosoxidans  +  blaOXA-114f
A7  2007  A.  xylosoxidans  +  blaOXA-114c
A8  2008  A.  xylosoxidans  +  blaOXA-114f
A9  2008  A.  xylosoxidans  +  blaOXA-114l
A10  2008  A.  xylosoxidans  +  blaOXA-114f
A11  2008  A.  xylosoxidans  +  blaOXA-114f
A12  2008  A.  xylosoxidans  +  blaOXA-114e
A13  2008  A.  xylosoxidans +  blaOXA-114l
A14  2001  A.  xylosoxidans  +  blaOXA-114c
A15  2001  A.  xylosoxidans +  blaOXA-114c
A16  2007  A.  xylosoxidans +  blaOXA-114f
A17  2006  A.  xylosoxidans  +  blaOXA-114a
A18  2006  A.  xylosoxidans  +  blaOXA-114a
A19  2007  A.  xylosoxidans  +  blaOXA-114i






















Conclusionsa Isolates identified by ST analysis. Data published previously14,19
nd  Denmark11,  A.  xylosoxidans  was  the  most  frequently
ecovered  species  from  the  airways  of  patients  with  cys-
ic  fibrosis.  A.  ruhlandii,  the  second  most  prevalent  species
dentified  in  this  study,  was  only  identified  in  3/96  patients
n  the  UK  and  none  in  Spain  and  France;  however  it  was  the
econd  most  prevalent  species  in  the  USA  and  Brazil.  The
eported  prevalence  for  A.  dolens  varies  between  2  to  17%,
ccounting  for  10%  in  the  present  study.  Discrepant  results
ere  observed  in  species  prevalence  in  different  countries,
he  local  distribution  being  more  similar  to  that  reported  in
razil.
All  isolates  included  in  this  study  were  resistant
o  quinolones  and  aminoglycosides,  while  piperacillin,
A
r
iperacillin/tazobactam  and  carbapenems  were  the  most
ctive  antibiotics,  as  it  had  been  previously  described  by
lmuzara  et  al.1 Fifty  percent  (50%)  of  the  isolates  were
esistant  to  trimethoprim-sulfamethoxazole  while  85%  were
esistant  to  colistin.  Moreover,  3/7  A.  ruhlandii  isolates  and
/26  A.  xylosoxidans  were  resistant  to  imipenem.  Antimi-
robial  MIC  values  for  the  Achromobacter  isolates  included
n  this  study  are  shown  in  table  S2  (supplementary  material).lthough  A.  xylosoxidans  was  the  most  common  species











Diversity  of  Achromobacter  species  in  patients  with  CF  
was  not  the  only  species  present  in  those  samples,  as  it  was
inferred  from  the  phenotypic  approaches  analyzed  in  this
study.  A.  ruhlandii  was  the  second  species  in  prevalence,  in
agreement  with  the  results  obtained  in  Brazil  and  USA.
MALDI-TOF  rendered  inconclusive  or  misleading  results
understating  the  presence  of  species  other  than  A.
xylosoxidans,  probably  due  to  commercial  databases,  key
components  of  MALDI-TOF  platforms,  which  are  constructed
with  a  low  number  of  isolates  mainly  corresponding  to  A.
xylosoxidans.  Their  expansion  should  be  crucial  to  resolve
many  of  the  current  inadequate  identifications,  improving
the  usefulness  of  this  technique.
On  the  other  hand,  concordant  results  were  achieved
with  nrdA  sequencing  or  ST  analysis,  and  the  blaOXA sequenc-
ing  approach  proposed  by  Traglia  et  al.19,  allowing  a  reliable
discrimination  among  the  different  Achromobacter  species,
and  demonstrating  that  a  wide  diversity  of  Achromobacter
spp.  may  colonize  and/or  infect  the  airways  of  patients  with
CF.  Although  the  MLST  scheme  constitutes  an  accurate  tool,
its  arduous  procedure  may  not  be  applicable  in  moderate
complexity  laboratories.  In  this  regard,  the  amplification
and  sequencing  of  a  single  gene,  nrdA  or  blaOXA,  may  be
more  pertinent.
The  susceptibility  profile  of  Achromobacter  spp.  indi-
cated  that  these  microorganisms  were  resistant  to  a  wide
range  of  antibiotics,  including  fluoroquinolones,  aminogly-
cosides  and  the  majority  of  broad-spectrum  -lactams.
Carbapenems  were  the  most  active  antibiotics;  however,  the
emergence  of  resistant  isolates  was  detected.  No  correla-
tion  could  be  established  among  the  susceptibility  profiles
and  Achromobacter  species.  Therefore,  the  antimicrobial
therapy  in  patients  with  CF  should  be  conducted  based  on
the  susceptibility  profile  of  individual  Achromobacter  spp.
isolates.
Finally,  prompt  and  accurate  identification  tools  should
provide  an  opportunity  to  understand  the  clinical  impact
of  the  different  Achromobacter  species  on  the  progression
of  respiratory  infections  in  patients  with  CF.  In  this  sense,
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